Serum immunoglobulin heavy/light chain (HLC) and free light chain (FLC) concentrations at diagnosis in multiple myeloma and IgM malignant lymphoma patients with survival exceeding 10 years
- 1 September 2012
- journal article
- Published by Walter de Gruyter GmbH in Acta Haematologica Polonica
- Vol. 43 (2), 201-209
- https://doi.org/10.1016/s0001-5814(12)33007-7
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- A 71-Year-Old Woman with Multiple Myeloma Status after Stem Cell TransplantationClinical Chemistry, 2011
- Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple MyelomaBlood, 2010
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 2010
- Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin κ/λ RatiosClinical Chemistry, 2009
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Prognostic value of serum free light chain ratio at diagnosis in multiple myelomaBritish Journal of Haematology, 2007
- Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and UrineClinical Chemistry, 2001